Hans‐Joachim Lück

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Jacobus Pfisterer, Marie Plante, Ignace Vergote et al. · Journal of Clinical Oncology · 2006 · 746 citations · Full text

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Peter Reichardt, Gϋnter von Minckwitz, Peter Thuss‐Patience et al. · Annals of Oncology · 2003 · 236 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +7

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

Jacobus Pfisterer, B. Weber, Rainer Kimmig et al. · JNCI Journal of the National Cancer Institute · 2006 · 208 citations

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt et al. · European Journal of Cancer · 2011 · 183 citations

Breast Oncology, Medicine, Pathology +7

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

Gϋnter von Minckwitz, W. Jonat, Peter A. Fasching et al. · Breast Cancer Research and Treatment · 2005 · 164 citations

Breast Oncology, Medicine, Pharmacology +6